Home » Newsletters » BioWorld Science

BioWorld Science

June 17, 2014

View Archived Issues

Novel antiviral drugs demonstrate efficacy against diverse RNA and DNA viral pathogens

Update on phase I trial of AG-221, a potent IDH2 mutant protein inhibitor

Fibrocell and Intrexon's epidermolysis bullosa cell therapy receives U.S. orphan drug status

Novel agents for parasitic diseases designed by IRM and Novartis

[18F]-GP1: a potential a PET tracer for thrombi in humans

PSMA ligand evaluated in patients for the diagnosis of prostate cancer

Novel PIKfyve inhibitor described by Astellas scientists

University of Cape Town discloses agents for tuberculosis

Biofordrug designs novel 5-HT7 receptor ligands

DiscoveryBiomed presents novel CFTR correctors for cystic fibrosis

GlaxoSmithKline divulges new DGAT1 inhibitors

New agents for allergic diseases designed at GlaxoSmithKline

New Omega-3 fatty acid analogues disclosed by the University of Sydney

Phase I data reported for Themis Bioscience's vaccine against Chikungunya fever

Aastom Biosciences outlines strategic plans for cell therapy and regenerative medicine business

Torii Pharmaceutical reports results from Japanese trials of house dust mite SLIT tablet

Rucaparib enters phase II trial in BRCA-mutant pancreatic cancer

Medtronic to acquire Covidien

FDA grants orphan drug designation to AG-221 for AML

Dainippon Sumitomo Pharma closes further enrollment in phase III colorectal cancer study

FDA and EMA accept applications for AbbVie's HCV regimen

Kringle initiates Japanese study of rhHGF in acute spinal cord injury

BL-8040 to be evaluated for stem cell mobilization in phase I trial

Vedolizumab enters U.S. market for ulcerative colitis and Crohn's disease

Convergence reports positive phase II data for sodium channel blocker analgesic

Gilead Sciences reports data from phase III study of ledipasvir/sofosbuvir in Japanese patients

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 11, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...